Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oral [14C] PF-07799544

Phase 1

Oral [14C] PF-07799544 is one of 7 therapeutic programs targeting Male. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

6

Competitors

Pipeline

Status by Indication[2][1]

Indication

MaleActive, not recruiting

MalePhase 1

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Male

#DrugCompanyPhaseTrials

Sensipar

Crestor

Pradaxa

Boehringer Ingelheim

Romvimza

DDeciphera Pharmaceuticals, LLC

Pradaxa

Boehringer Ingelheim

Oral [14C] PF-07799544

Chf10196

Chiesi Farmaceutici S.p.A.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unspecified1 trial

A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT PARTICIPANTS TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-07799544 USING A 14C-MICROTRACER APPROACH

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT07578636·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oral [14C] PF-07799544. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Oral [14C] PF-07799544. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Pfizer

Related News